The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. - Test2 - elhamkhani - TriplyDB

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

http://www.wikidata.org/entity/Q40012022

about

Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation The Role of Oxidative Stress and Antioxidants in Liver Diseases Molecular mechanisms underlying occult hepatitis B virus infection.Antiviral drug resistance: mechanisms and clinical implications Genotyping and molecular characterization of hepatitis B virus from human immunodeficiency virus-infected individuals in southern Africa Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.Novel nucleotide and amino acid covariation between the 5'UTR and the NS2/NS3 proteins of hepatitis C virus: bioinformatic and functional analyses.Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Complex dynamics of hepatitis B virus resistance to adefovir.Acyclic nucleoside phosphonates: a key class of antiviral drugs.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Profile of hepatitis B virus resistance mutations against nucleoside/nucleotide analogue treatment in Chinese patients with chronic hepatitis B.High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus.An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients HIV-1 quasispecies delineation by tag linkage deep sequencing Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?Establishment of drug-resistant HBV small-animal models by hydrodynamic injection Antiviral therapies: focus on hepatitis B reverse transcriptase Mutations affecting the replication capacity of the hepatitis B virus.Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study.Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.Overview of hepatitis B viral replication and genetic variability Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.Antiviral resistance and hepatitis B therapy.Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach.Serologic and genotypic characterization of hepatitis B virus in HIV-1 infected patients from South West and Littoral Regions of Cameroon.Genotyping and Mutation Pattern in the Overlapping MHR Region of HBV Isolates in Southern Khorasan, Eastern Iran.Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.

P2860

Q24806372-64E42C63-7B7C-4841-B6FC-15E1C7585876 Q26772036-BB65B580-B7F1-4B09-B3C9-0BE75CB31BFA Q26779146-E3DFAF5B-1DC3-4619-89F6-A996B36AE05D Q27686923-BDB6B6C8-AC5B-41C4-B7D4-991357BCEE3D Q28282376-E9ED7771-954F-4823-8716-355B56BCE745 Q28484102-712C9CE0-9E41-4C4F-9EAC-B111E8CC6452 Q28535003-55C4DA27-27B4-48A1-AF83-8BC8B7BEBB79 Q28547647-BB1FDCE7-A72C-4DD3-A9BC-87F2CA1DC97E Q33206221-EA67C9CD-976E-4B43-AEEA-8EE4FEE9F71C Q33826784-06487C5F-10E4-4DEC-B3A2-622444BCA808 Q33950133-BFA93A1F-B597-41BB-B818-8EBB2E4B943B Q34043316-96AFD33E-F7E2-445C-BDA4-312806E8219C Q34045308-4E1AC6D4-38A4-458F-A165-07164044C96B Q34208672-051F6358-D2C0-4C65-AE01-C48C2C13AE22 Q34464655-53AF3092-A300-4172-B51D-25B89B091F7D Q34489239-434C5F91-583A-452A-B68B-3D0D3FB37122 Q34508158-AD53B616-F485-4609-BF34-D2234D959DFB Q34997985-CDD61E0C-D68F-4E57-B0EC-86229ABCD3EE Q35102963-79DB01EC-3A43-4D27-8BE0-CE75C2B57AD5 Q35171177-61A8CD0E-375C-4584-92CC-C3557885D7D4 Q35433965-F3C27FD3-4CF4-474A-985B-18C5ACE07EBF Q35603841-5A303099-F9A3-49BE-9EEF-AB04A96BA384 Q35721334-851842A2-8A7D-4816-886F-BA7EF5B00C7B Q35879053-D0A323C0-1266-4CAB-AC7D-37DC3C619CB8 Q35964704-06DF9757-713F-4334-BB44-94544D5A32DC Q36007344-0CEEDF0D-03F1-4A5A-B3A8-D41DA7EBB918 Q36237555-F949FC8C-08AA-46CE-A575-E15916E3FA4B Q36467514-8F99BFCE-9E13-4CEC-A443-AC1BFE471D12 Q36515349-02F399DE-1CC1-43F0-AD5D-7CE212712056 Q36698116-601DC406-A4DD-4679-BE10-47D20C51A064 Q36765571-2B67DE3C-D555-488C-81FE-4DD9659D4DC4 Q36807341-D8D34FD3-B8DB-44BD-B72D-C8B8B9E08931 Q36980718-F02CAA89-5199-42E8-B366-9F6C61A7702E Q37158625-B3D0509B-CE9B-43C5-B9D3-D3A08F9F237E Q37255008-C2454F59-C459-44FA-A6C3-2A4924936CBF Q37285249-3B8D5A00-BABC-414D-817E-D7F07C1FD860 Q37355830-97485100-FEEC-4571-81CD-E8CA43B1611A Q37417336-3377DCBE-6344-421A-ACBD-54BC171848C1 Q37502756-9BDD570C-124B-4C93-86CC-A401D3AC616E Q37678183-DD3C1865-2A1C-483D-A6D3-CEC83CFFE3DA

P2860

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

http://www.wikidata.org/entity/Q40012022

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

The hepatitis B virus polymera ...... es viral replication in vitro.

@en

type

label

The hepatitis B virus polymera ...... es viral replication in vitro.

@en

prefLabel

The hepatitis B virus polymera ...... es viral replication in vitro.

@en

P1433

Q40012022-E0284DAB-8D04-4480-99F0-1854F7FA200E

P1476

Q40012022-8D94C591-EA7B-4665-A61F-C070EA18EFF3

P2093

Q40012022-100327E8-25DA-4FBF-92A5-CE07E413C493

Q40012022-41DC6D59-8E1D-43E3-862A-4569CC9D6477

Q40012022-684A50A0-301E-4390-8AEB-57BC9EF333AD

Q40012022-72DC4000-A55E-43E8-9518-285017766D6A

Q40012022-A7836095-82C7-4ECA-AA9F-DF0B7EDE744B

Q40012022-BA111E35-8278-4AB8-8DD7-59A11DCDCAE5

Q40012022-F3C4D92F-62AF-46BE-8823-D84EBB043E42

P2860

Q40012022-0D29CDE9-A0B3-4657-BF87-CC22DF4429D4

Q40012022-265C6FAF-2EF4-4F08-A7EC-3BAA19E7E5E8

Q40012022-29F05586-9256-43FC-96A7-9DA824A50744

Q40012022-2CCC3EBD-23C3-403B-B807-C754A45312B4

Q40012022-313F8D47-3B9E-43FC-82D4-8460B9DD12BC

Q40012022-3D43D242-08C6-4576-9428-ADDF4A0EEE47

Q40012022-4326F237-AA36-4526-8D30-3351D28B2A79

Q40012022-4396CC36-9B86-4080-80D8-F312ECB863F1

Q40012022-4408C6C2-E8CD-4714-B05D-9EBF10E799CE

Q40012022-472388AB-C96D-40D4-84CE-D50848B0EE97

P304

Q40012022-BA72AA09-CE28-4E17-9A70-6E72F1F172E8

P31

Q40012022-9DC4B403-2B51-488B-A791-917158569841

P356

Q40012022-9E329D3E-44E9-4250-A636-62F1649BE35A

P407

Q40012022-57DFB074-91B5-4E21-8987-371529313F15

P433

Q40012022-9BB037DB-D2B4-42F1-B0E5-80F49BF90787

P478

Q40012022-9DC965A7-2627-46FC-86DC-60F6A56EC6A0

P50

Q40012022-03927E4E-DB12-4ADA-BF57-A84844E5D6D0

P577

Q40012022-C980F651-3390-48F7-A43D-A395573AF732

P698

Q40012022-D1E2244D-547B-4A2E-B18B-02631B24E750

P932

Q40012022-DFDD6672-A4C6-4F4C-8A8B-93C422C1B3FF

P356

JVI.77.21.11833-11841.2003

P1433

Journal of Virology

P1476

The hepatitis B virus polymera ...... ces viral replication in vitro

@en

P2093

Christopher E Westland

http://www.w3.org/2001/XMLSchema#string

Craig S Gibbs

http://www.w3.org/2001/XMLSchema#string

Eddy Arnold

http://www.w3.org/2001/XMLSchema#string

Huiling Yang

http://www.w3.org/2001/XMLSchema#string

Michael D Miller

http://www.w3.org/2001/XMLSchema#string

Shelly Xiong

http://www.w3.org/2001/XMLSchema#string

William E Delaney

http://www.w3.org/2001/XMLSchema#string

P2860

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus

Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile an

A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen.

P304

11833-11841

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.77.21.11833-11841.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14557667

http://www.w3.org/2001/XMLSchema#string

P932

229343

http://www.w3.org/2001/XMLSchema#string